Investigación científica sobre terapia celular aplicada a la osteoartritis de rodilla

Cell Therapy for Osteoarthritis

A study published in the scientific journal Science Advances proposes a new mechanism to address knee osteoarthritis, co-authored by Dr. Teresita Moviglia —LYRACELL’s scientific lead—. The study had international impact: scientist and Forbes columnist William A. Haseltine devoted two articles to it. In this article we explain what it is about.

What is osteoarthritis and why is it hard to treat?

Knee osteoarthritis often develops after trauma that damages the joint cartilage. The problem is that this tissue has a naturally limited capacity to regenerate, and when the damage is not repaired, the condition can become chronic.

According to the research, much of that difficulty lies in the synovial fluid: it contains a high level of pro-inflammatory cells and a very low level of pro-regenerative cells, an imbalance that prevents the body from repairing the damage in the knee on its own.

The research: mesenchymal stem cells and effector lymphocytes

The study “The synovial environment steers cartilage deterioration and regeneration” (Bolander, J., Moviglia, M.T. et al., Science Advances, 2023), carried out together with Wake Forest School of Medicine, proposes an approach based on laboratory pre-differentiated mesenchymal stem cells together with effector lymphocytes. Once implanted in the affected area, they aim to reverse that cellular imbalance in the synovial fluid and activate the cartilage repair process.

It is the same biological principle behind the Moviglia Method: an autologous-based treatment, with cells prepared in the laboratory and specifically directed toward the tissue that needs to be repaired.

International impact: Forbes coverage

Scientist William A. Haseltine —a Harvard Medical School graduate with an extensive career in cancer and HIV research, and a science and medicine columnist at Forbes— devoted two articles to this research. In the first, he describes how inflammation of the synovial fluid inhibits cartilage repair; in the second, he analyzes in detail the therapeutic proposal by Bolander, Moviglia and their team, describing it as a significant advance in research on the treatment of osteoarthritis.

It is worth emphasizing: this is scientific research in progress, not a treatment with guaranteed results. Every advance like this adds evidence, but the indication for any cell therapy always depends on an individual medical evaluation.

Frequently asked questions

What did the research reveal about osteoarthritis?

It identified that the imbalance between pro-inflammatory and pro-regenerative cells in the synovial fluid hinders the natural repair of cartilage, and proposed a cell-based approach to reverse that imbalance.

Who is Dr. Teresita Moviglia and what role did she play in this research?

She is a clinical immunologist, President of ACIDTA and LYRACELL’s scientific lead. She is a co-author of the study published in Science Advances.

Where was the study published?

In the scientific journal Science Advances, in 2023, together with researchers from Wake Forest School of Medicine. You can see this and other publications in Research and Publications.

Does this mean there is now a definitive treatment for osteoarthritis?

No. This is research in progress. It adds evidence about a possible mechanism, but any treatment indication always depends on an individual medical evaluation.

Do you have knee pain or limited mobility? A medical evaluation makes it possible to identify the cause and determine whether cell therapy for the knee may be an option for your case.

Request a Medical Evaluation →

Real research, measured expectations

Having a study co-authored by our scientific lead published in a journal like Science Advances and covered by Forbes is an important validation of the Moviglia Method’s research path. But the evidence is still evolving, and each treatment indication is always defined individually.